SANDOSTATIN LAR has a well-established adverse event profile1,2
Adverse events are predictable and manageable1
During SANDOSTATIN LAR treatment, the most common adverse reactions reported include:1
Adverse drug reactions reported in clinical studies1
|Adverse drug reactions||Very common (≥1/10)||Common (≥1/100)||Uncommon (≥1/1,000, <1/100)|
|Gastrointestinal disorders||Diarrhoea, abdominal pain,nausea, constipation, ﬂatulence||Dyspepsia, vomiting, abdominal bloating, steatorrhoea, loose stools, discolouration of faeces||–|
|Nervous system disorders||Headache||Dizziness||–|
|Endocrine disorders||–||Hyperthyroidism, thyroid disorder||–|
|Hepatobiliary disorders||Cholelithiasis||Cholecystitis, biliary sludge, hyperbilirubinaemia||–|
|Metabolism and nutrition disorders||Hyper glycaemia||Hypoglycaemia, impaired glucosetolerance, anorexia||Dehydration|
|General disorders and administration site conditions||Injection site reactions||Asthenia||–|
|Investigations||–||Elevated transaminase levels||–|
|Skin subcutaneous tissue disorders||–||Pruritus, rash, alopecia||–|
For more information, refer to the SANDOSTATIN® LAR® (octreotide acetate) Summary of Product Characteristics
- SANDOSTATIN® LAR®. Summary of Product Characteristics. December 2020.
- Rinke A, et al. J Clin Oncol. 2009;27:4656–4663.